<DOC>
<DOCNO>EP-0907651</DOCNO> 
<TEXT>
<INVENTION-TITLE>
ANTINEURODEGENERATIVE ERGOLINE DERIVATIVES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3148	A61K3148	C07D45700	C07D45702	C07D45710	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	C07D457	C07D457	C07D457	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention provides the new use in the treatment of neurodegenerative diseases with ergoline derivatives of formula (I) wherein R1 represents a hydrogen atom or a linear or branched C1-C5 alkyl or C2-C5 alkenyl group optionally substituted with a C3-C7 cycloalkyl, a hydroxy group or a R3-substituted phenyl group wherein R3 is a hydroxy or a hydroxymethyl group; R2 represents a hydrogen atom or a linear or branched C1-C5 alkyl or a C2-C5 alkenyl group optionally substituted with a hydroxy group, or a R3-substituted phenyl group wherein R3 is as above defined, or with a C1-C5 alkoxy group; the symbols -- at positions 2,3 and 8, 9 independently denote a single or double chemical bond and Z represents a group (CH2)nOH, wherein n is 0 or an integer from 1 to 3, or a group C(R4)2OH wherein R4 is a C1-C5 alkyl or a phenyl group, or a pharmaceutically acceptable salt thereof. Some compounds of formula (I) are novel. Processes for their preparation and pharmaceutical compositions containing them are also described.
 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
PHARMACIA 
&
 UPJOHN SPA
</APPLICANT-NAME>
<APPLICANT-NAME>
PHARMACIA 
&
 UPJOHN S.P.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BRAMBILLA ENZO
</INVENTOR-NAME>
<INVENTOR-NAME>
CARFAGNA NICOLA
</INVENTOR-NAME>
<INVENTOR-NAME>
MANTEGANI SERGIO
</INVENTOR-NAME>
<INVENTOR-NAME>
VARASI MARIO
</INVENTOR-NAME>
<INVENTOR-NAME>
BRAMBILLA, ENZO
</INVENTOR-NAME>
<INVENTOR-NAME>
CARFAGNA, NICOLA
</INVENTOR-NAME>
<INVENTOR-NAME>
MANTEGANI, SERGIO
</INVENTOR-NAME>
<INVENTOR-NAME>
VARASI, MARIO
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 An ineurodegenerative Ergoline DerivativesThe present invention relates to the treatment of neurodegenerative diseases employing ergoline derivatives, to new ergoline derivatives for such a treatment, to a process for preparing them and to their pharmaceutical acceptable salts.The present invention relates to the therapeutic use, in the treatment of neurodegenerative diseases, of ergoline derivatives of formula I
 whereinRi represents a hydrogen atom or a linear or branched C C5 alkyl or C2-C5 alkenyl group optionally substituted with a C3-C7 cycloalkyl, a hydroxy group or a R3- substituted phenyl group wherein R3 is a hydroxy or a hydroxymethyl group;R2 represents a hydrogen atom or a linear or branched C1-C5 alkyl or a C2-C5 alkenyl group optionally substituted with a hydroxy group, a R3- substituted phenyl group wherein R3 is as above defined, or with a C C5 alkoxy group; the symbols ~ at positions 2,3 and 8, 9 independently denote a single or double chemical bond and Z represents a group (CH2)nOH, wherein n is 0 or an integer from 1 to 3, or a group C R-^OH wherein R-» is a C C5 alkyl or a phenyl group, or a pharmaceutically acceptable salt thereof. 

 The wavy line ( — ) in formula I indicates that the substituent in the 8- or 10- position may be either in the α-configuration, i.e. below the plane of the ring, or in the β-configuration, i.e. above the plane of the ring.In a fiirther aspect of the present invention, there are provided novel ergoline 5 derivatives of formula I as above defined, characterised in that the following compounds are excluded.6-methyl-8β-hydroxy- 1 Oα-methoxy-ergoline,6-methyl-8β-hydroxymethyl- 1 Oβ-methoxy-ergoline,6-methyl-8β-hydroxymethyl- 1 Oα-methoxy-ergoline, l o 6-methyl-8α-hydroxymethyl- 1 Oα-methoxy-ergoline,6-methyl-8β-hydroxymethyl-l 0α-( 1 -methylethoxy)-ergoline,6-methyl-8β-hydroxymethyl- 1 Oα-hydroxy-ergoline,6-methyl-8β-hydroxymethyl- 1 Oβ-hydroxy-ergoline,6-methyl-8β-hydroxymethyl- 10α-methoxy-Δ-8,9-ergolene 15 8β-hydroxymethyl-l Oα-methoxy-ergoline,6-methyl-8β-hydroxyethyl-l Oα-methoxy-ergoline, and6-methyl-8β-hydroxymethyl- 1 Oα-propoxy-ergoline.More preferably there are provided ergoline derivatives of formula I as above depicted, characterised in that Z is not a hydroxy, hydroxymethyl or 20 hydroxyethyl group, when Ri is hydrogen, or a methyl group, R2 is hydrogen or a methyl, propyl, isopropyl group, ~ at 2, 3 position is a double bond and ~ at 8,9 position represents a single or a double bond.In the present specification, the term C1-C5 alkyl group
</DESCRIPTION>
<CLAIMS>
CLAIMS
1. Use of ergoline derivatives of formula I

 wherein
Ri represents a hydrogen atom or a linear or branched Cj-Cs alkyl or C
2
- C
5
 alkenyl group optionally substituted with a C
3
-C
7
 cycloalkyl, a hydroxy group or a R
3
- substituted phenyl group wherein R
3
 is a hydroxy or a hydroxymethyl group; R2 represents a hydrogen atom or a linear or branched C
1
-C
5
 alkyl or a
C
2
-C
5
 alkenyl group optionally substituted with a hydroxy group, or a R
3
- substituted phenyl group wherein R
3
 is as above defined, or with a -C
5
 alkoxy group; the symbols — at positions 2,3 and 8, 9 independently denote a single or double chemical bond and Z represents a group (CH )
n
OH, wherein n is 0 or an integer from 1 to 3, or a group C(R
4
)
2
OH wherein R
4
 is a C
1
-C
5
 alkyl or a phenyl group, or a pharmaceutically acceptable salt thereof, for treatment of neurodegenerative diseases.
2. Use according to claim 1 wherein Rj is hydrogen atom, methyl, 2 hydroxyethyl or (2-hydroxy-2-phenyl)ethyl group; R
2
 is hydrogen atom or methyl, 1 -methylethyl, propyl, 2-hydroxyethyl, 3-hydroxypropyl, 2- methoxyethyl group, Z is a group (CH
2
)
n
 OH, or C(1Γ
M
)
2
OH, n is O, 1 or 2, R
4
 is methyl or phenyl group. 

3. Use according to claim 1 or 2, in the treatment of Alzheimer's diseases, Down's syndrome, dementia, memory disturbancies.
4. An ergoline derivative of formula I, as defined in claim 1 with the 5 exclusion of 6-methyl-8β-hydroxy-l Oα-methoxy-ergoline,
6-methyl-8β-hydroxymethyl- 1 Oβ-methoxy-ergoline,
6-memyl-8β-hyo!roxymethyl-10α-methoxy-ergoline,
6-methyl-8α-hydroxymethyl- 1 Oα-methoxy-ergoline,
6-methyI-8β-hydroxymethyl-10α-(l-methylethoxy)-ergoline, l o 6-methyl-8β-hydroxymethyl- 1 Oα-hydroxy-ergoline,
6-methyl-8β-hydroxymethyl- 1 Oβ-hydroxy-ergoline,
6-methyl-8β-hydroxymethyl- 10α-methoxy-Δ-8,9-ergolene
8β-hydroxymethyl- 1 Oα-methoxy-ergoline,
6-methyl-8β-hydroxyethyl-l Oα-methoxy-ergoline, and 15 6-methyl-8β-hydroxymethyl- 1 Oα-propoxy-ergoline.
5. An ergoline derivative of formula I, as defined in claim I characterized in that Z is not a hydroxy, hydroxymethyl or hydroxyethyl group when R] is hydrogen, or a methyl, propyl group, R
2
 is hydrogen or a methyl, propyl,
20 isopropyl group, — at 2, 3 position is a double bond and - at 8,9 position represents a single or a double bond.
6. A process for preparing a compound of formula I as defined in claim 4 or 5 or a pharmaceutically acceptable salt thereof, which process compπses
25 preparing the said ergoline of formula I from a known ergoline by means of an 


appropriate chemical modification and, if desired, converting the resulting ergoline of formula I into a pharmaceutically acceptable salt thereof.
7. A process for the preparation of a compound of formula I as defined in claim 4 wherein Z is a hydroxy group and the symbol — at 9, 10 position is a single bond, or a pharmaceutically acceptable salt thereof, which comprises:
( 1 ) reacting a compound of formula Ha
wherein R
5
 is C
1
-C
5
 alkyl group and — and Rj and R are as defined in claim
4, with hydrazine and treating the resultant 8-hydrazide derivative with a nitrite salt in acidic conditions,
(2) treating the resultant 8-amino derivative of the formula III

 wherein — and Ri and R are as defined above, with a nitrite salt in the presence of acetic acid, and hydrolysing the resultant 8-acetyloxy derivative and, if desired, (3) converting a resultant compound of formula I 


 wherein — and Ri are as defined above and R
2
 is a methyl group, into a compound of formula I wherein R
2
 is different from methyl, by treatment with a compound of formula R -OH in the presence of an acid, and, if desired, converting the resultant said compounds of formula I into a pharmaceutically acceptable salt thereof.
8. A process for the preparation of a compound of formula I, as defined in claim 4 wherein Z is a group of formula (CH
2
)
n
OH, with n 1 or 2, or a pharmaceutically acceptable salt thereof , which comprises:
( 1 ) reducing a compound of formula II

 wherein — R R
2
 and R5 are as defined in claim 7, and, if desired,
(2) treating the resultant compound of formula I, wherein Z represents CH
2
OH, with methanesulphonylchloride;
(3) reacting the resultant compound of formula IV 


 wherein Ri, R
2
 and — are as defined above, with KCN,
(4) reacting with an acid the resultant compound of formula V

 wherein Rj, R
2
, and ~ are as defined above, in the presence of an alcohol of the formula R5-OH, wherein R5 is as above defined; (5) reducing the resultant compound of formula VI

 wherein Ri, R
2
, R
5
 and — are as defined above, and, if desired, converting the resultant compound of formula I wherein Z is CH
2
CH
2
OH or CH
2
OH, as obtained above under step (1), into a pharmaceutically acceptable salt thereof.
9. A process for the preparation of a compound of formula I as defined in claim 4 wherein Z is CH
2
CH
2
CH
2
OH, or a pharmaceutically acceptable salt thereof, which comprises: (1) condensing a compound of formula IV as defined in claim 8 with a 


di-Cj-C
5
 alkylmalonate salt;
(2) heating the resultant compound of formula VII

 wherein R), R
2
, R
5
 and — are as defined above,
(3) reducing the resultant compound of formula VIII

 wherein Ri, R
2
, R
5
 and — are as defined above, and, if desired, converting the resultant compounds of formula I into a pharmaceutically acceptable salt thereof. 10. A process for the preparation of a compound of formula I, as defined in claim 4 wherein Z is a group of formula C(R-
t
)
2
OH, wherein R is as defined in claim 4, or a pharmaceutically acceptable salt thereof, which comprises: (1) condensing a compound of formula II as defined in claim 8 with a Grignard reagent of formula R-αMgBr wherein R
4
 is as defined above, and, if desired, converting the resultant said compound of formula I into a pharmaceutically acceptable salt thereof.
11. A process for the preparation of a compound of formula I as defined in claim 4 wherein — at 8, 9 position is a single bond, which comprises converting a compound of formula IX 

wherein — , Ri and Z are as defined in claim 4, by photochemical addition of a compound of formula R -OH, wherein R
2
 is as defined in claim 4, in the presence of an acid, and, if desired, converting the resultant said compounds of formula I into a pharmaceutically acceptable salt thereof.
12. A pharmaceutically composition which comprises, as active ingredient, an ergoline of formula I as defined in claim 4 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or diluent.
13. An ergoline derivative of formula I as defined in claim 4 or a pharmaceutically acceptable salt thereof for use in the treatment of neurodegenerative diseases. 

</CLAIMS>
</TEXT>
</DOC>
